Early start and stop of biologics: has the time come?

被引：0

作者：

Ronald F van Vollenhoven

György Nagy

Paul P Tak

机构：

[1] The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID)

[2] Semmelweis University,Department of Genetics, Cell, and Immunobiology, Faculty of Medicine

[3] Semmelweis University,Department of Rheumatology

[4] Medical School,Academic Medical Center

[5] University of Amsterdam,undefined

[6] University of Cambridge,undefined

[7] GlaxoSmithKline,undefined

来源：

BMC Medicine | / 12卷

关键词：

Biologics; Rheumatoid arthritis; Treatment;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Despite considerable advances in the management of rheumatoid arthritis, results are still not satisfactory for all patients. The treatment goal in rheumatoid arthritis is remission, and there currently are numerous conventional and biological medications available to reach this aim. There are also different treatment strategies but with only limited comparative evidence about their efficacies. More patients now achieve remission while on treatment, but it remains elusive in the majority of patients. Treatment-free remission, the ultimate goal of therapy, is only achieved in very few patients; even when this happens, it is most likely due to the natural course of the disease rather than to any specific therapies. Modern treatment is based on the initiation of aggressive therapy as soon as the diagnosis is established, and on modifying or intensifying therapy guided by frequent assessment of disease activity. In this commentary we will discuss the current treatment paradigm as well as the possibility of an induction-maintenance regimen with biological disease-modifying antirheumatic drugs in early rheumatoid arthritis.

引用

共 67 条

[1]

Smolen JS(2010)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Ann Rheum Dis 69 964-975

[2]

Landewe R(2001)Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis? Best Pract Res Clin Rheumatol 15 17-26

[3]

Breedveld FC(1995)Joint erosions and patients with early rheumatoid arthritis Br J Rheumatol 34 74-78

[4]

Tak PP(2008)American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762-784

[5]

van der Heijde DM(2004)Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 3432-3443

[6]

Saag KG(2006)The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 26-37

[7]

Teng GG(2004)Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675-681

[8]

Patkar NM(2009)Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial Lancet 374 459-466

[9]

St Clair EW(2012)Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial Lancet 379 1712-1720

[10]

van der Heijde DM(2012)A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial Arthritis Rheum 64 2824-2835

← 1 2 3 4 5 6 7 →